Clinical TrialsBioXcel Therapeutics is expanding the potential use of its FDA-approved drug IGALMI™ through the SERENITY III Phase 3 trial, aiming to make the treatment available for at-home use, which could benefit millions more patients.
Drug EfficacyThe 60µg dose of BXCL501 has demonstrated solid safety and tolerability in previous trials, potentially indicating a lower risk profile for the upcoming TRANQUILITY In-Care Phase 3 trial for Alzheimer's disease agitation.
Financial HealthBTAI's recent $25 million equity raise and subsequent cash runway extension into the fourth quarter of 2024 position the company to continue its clinical programs without immediate financial constraints.